TheraRadar
← Back
Data updated: Jun 28, 2026

AIRGAS CARBONIC INC

Pharma
Pharmaceuticals

AIRGAS CARBONIC INC is a pharmaceutical company with 1 FDA-approved products.

2013
Since
1
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
1 Small Molecules

AIRGAS CARBONIC INC's Key Drugs

AIRGAS CARBONIC INC's core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013

AIRGAS CARBONIC INC's Recent FDA Approvals

AIRGAS CARBONIC INC secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

AIRGAS CARBONIC INC's Therapeutic Areas

Disease areas where AIRGAS CARBONIC INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

AIRGAS CARBONIC INC Pipeline Snapshot

Active clinical trials for AIRGAS CARBONIC INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling